Proteomics

Dataset Information

0

Dissecting Alzheimer’s disease molecular substrates by proteomics and discovery of novel post-translational modifications (PTMs)

ABSTRACT: Protein post-translational modifications (PTMs) serve as diagnostic markers in Alzheimer’s disease. We aimed to discover new PTMs in the context of this disease from MS/MS-based proteomic datasets. Publicly available label-free proteomics data were searched for select PTMs using SEQUEST-HT. Only high-confidence PTMs were analyzed further using bioinformatics analysis. We identified 4,961 unique modified peptides corresponding to 1,856 proteins from datasets pertaining to Alzheimer’s disease. Of these, 52 proteins were known to be involved in Alzheimer’s pathway. Also, 3,164 PTMs are reported to be novel in the context of this disease. Further, protein quantification reveals expression of 13 high-abundant secretary proteins across multiple studies which can be exploited as biomarkers. Identification of novel PTMs from the publicly available proteomic data may provide novel molecular insights in the progression and management of Alzheimer’s disease. Novel high abundant secretory proteins identified can be candidate CSF biomarkers in Alzheimer’s disease.

INSTRUMENT(S): Orbitrap Fusion ETD, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Cerebrospinal Fluid

DISEASE(S): Alzheimer's Disease

SUBMITTER: Keshava Prasad T. S.  

LAB HEAD: T. S. Keshava Prasad

PROVIDER: PXD014042 | Pride | 2019-11-06

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.

Deolankar Sayali Chandrashekhar SC   Patil Arun H AH   Koyangana Shashanka G SG   Subbannayya Yashwanth Y   Prasad Thottethodi Subrahmanya Keshava TSK   Modi Prashant Kumar PK  

Omics : a journal of integrative biology 20190621 7

Alzheimer's disease (AD) is a common complex disease and a major public health burden in both developed and developing countries. Postgenomic technologies such as proteomics and intelligent mining of multi-omics Big Data offer new prospects for diagnostics and therapeutics innovation for AD. In this context, it is noteworthy that mass spectrometry (MS) data are often searched against proteomics databases to unravel the identity of protein biomarkers. In contrast, only a fraction of the MS data c  ...[more]

Similar Datasets

Genomics Methanosphaera
| PRJNA362975 | ENA
Proteomics Quantitative PTM Maps of Human Pathologic Tau Identify Patient Heterogeneity and Define Critical Steps in Alzheimer’s Disease Progression - MC1-isolated Tau
2020-12-04 | PXD020482 | Pride
Proteomics Improved functional annotation of posttranslationally modified proteins
2020-07-02 | PXD002800 | Pride
Proteomics Quantitative PTM Maps of Human Pathologic Tau Identify Patient Heterogeneity and Define Critical Steps in Alzheimer’s Disease Progression - high/low molecular weight tau
2020-12-04 | PXD020483 | Pride
Genomics Assembly of cell fusing agent virus from publicly available sequencing datasets
| PRJEB33801 | ENA
Genomics,Multiomics Homo sapiens
| PRJNA279526 | ENA
Genomics Curcumin and novel synthetic analogs in Alzheimer’s disease prevention
| PRJNA505258 | ENA
Proteomics Quantitative PTM Maps of Human Pathologic Tau Identify Patient Heterogeneity and Define Critical Steps in Alzheimer’s Disease Progression - angular gyrus
2020-12-04 | PXD020517 | Pride
Proteomics Posttranslational modifications mediate the structural diversity of tauopathy strains
2020-02-14 | PXD016862 | Pride
Genomics Intergenic Disease-associated Regions are Abundant in Novel Regulatory Transcripts
| PRJEB21619 | ENA